Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Dyadic International highlights growing interest in its proprietary C1 protein production platform driven by intensified Ebola virus outbreak preparedness and expanding commercial adoption across multiple markets. The platform's rapid development capabilities support expedited vaccine antigen and monoclonal antibody production, aligning with global…
Lifecore Biomedical announced a new agreement with a global pharmaceutical company to perform tech transfer and commercial manufacturing for a neurological injectable suspension. This marks Lifecore's seventh late-stage pipeline addition in seven months, underscoring strong business momentum and expertise in complex injectable products, particularl…
Pasithea Therapeutics announced its participation as an exhibitor at the Children's Tumor Foundation 2026 NF Conference to engage with the neurofibromatosis type 1 (NF1) community following recent FDA Fast Track and Rare Pediatric Disease Designations for PAS-004, their next-generation macrocyclic MEK inhibitor. The company is currently conducting …
IREN Limited has completed the acquisition of Nostrum Group, a Spain-based AI data center developer, marking its entry into the European market and significantly boosting its AI cloud infrastructure capacity with 490MW of secured grid-connected power and a strong local team.
Lightbridge Corporation announced CEO Seth Grae's participation in upcoming investor and nuclear industry events, discussing the impact of advanced nuclear fuel technology on increasing reactor output and supporting clean energy goals. The company emphasizes its partnerships with US national labs and its patented nuclear fuel technology aimed at im…
Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P immunotherapy in adjuvant mKRAS-driven pancreatic cancer did not meet the primary disease-free survival endpoint in the intent-to-treat population. However, post-hoc analyses revealed a significant benefit in patients with R0 resection, who represent the majority of the s…
Seer, Inc.'s Board of Directors has issued a letter to shareholders ahead of the July 28, 2026 Annual Meeting, urging a vote in favor of the current board slate amid activist investor attempts to replace directors and push for a sale. The letter highlights Seer's pioneering leadership in proteomics technology, ongoing large-scale scientific studies…
Axsome Therapeutics presented new clinical data on its sleep disorder medicines AXS-12 and solriamfetol at SLEEP 2026, highlighting positive cognitive, functional, and quality-of-life outcomes in narcolepsy and obstructive sleep apnea patients. These presentations reinforce Axsome's leadership in central nervous system disorder treatments and its i…
Lexeo Therapeutics announced the finalization of the SUNRISE-FA 2 pivotal trial protocol and statistical plan for its gene therapy candidate LX2006 in treating Friedreich Ataxia cardiomyopathy. The open-label study aims to support a Biologics License Application to the FDA under the accelerated approval pathway targeted for 2028. Enrollment is on t…
Gogo Inc. announced that its Gogo Galileo connectivity system has received Supplemental Type Certificates from both the FAA and EASA for installation on Dassault Falcon 7X and 8X aircraft. This approval enables the installation of Gogo's high-performance inflight internet service powered by the Eutelsat OneWeb LEO network, offering reliable speeds …
TransAlta Corporation's subsidiary, TransAlta Centralia Generation LLC, has been mandated by the U.S. Department of Energy to keep Centralia Unit 2 in Washington State available for operation until September 13, 2026. The company will comply with this order and coordinate with the DOE and local government accordingly.
Village Farms International provided an operational update on its Delta 2 (D-2) greenhouse expansion in British Columbia, announcing a successful first harvest and commencement of cultivation in the second half of the expansion. The company plans accelerated technology upgrades, originally scheduled for 2027, to be completed in Q4 2026 without addi…
Tilray Brands, Inc. has launched a fan-engagement promotion called ‘Shocking Upsets’ for its Shock Top beer brand during the summer soccer tournament. The promotion offers rebates to consumers who purchase Shock Top and receive a rebate if a lower-ranked team defeats a top-10 ranked team, enhancing fan excitement and brand interaction. This campaig…
Coda Octopus Group, Inc. reported a slight decline in total revenue for fiscal second quarter 2026 compared to the previous year, mainly due to reduced sales in its Marine Technology business affected by geopolitical conflicts in the Middle East and Asia. However, the company achieved significant improvements in net income, operating income, and ea…
USA Rare Earth, Inc. (Nasdaq: USAR) has commissioned its hydrometallurgical demonstration facility in Wheat Ridge, Colorado, targeting first production of separated heavy rare earth oxides such as dysprosium, terbium, and yttrium by the third quarter of 2026. This marks a significant step toward building a fully integrated rare earth supply chain o…
Natural Gas Services Group, Inc. (NYSE: NGS) announced the $120 million acquisition of Flatrock Compression Holdings, expanding its rental compression services with additional large horsepower and electric motor units primarily in the Permian Basin and Eagle Ford regions. The acquisition diversifies NGS's customer base, increases operational densit…
XORTX Therapeutics announced the appointment of Mika Grasso as Co-CEO to enhance finance and public market strategies. The company is focusing on progressing its lead gout drug XRx-026 through regulatory filings and clinical studies, aiming for FDA new drug application submission. XORTX is also advancing its pipeline targeting progressive kidney di…
Tiziana Life Sciences' Executive Chairman, Mr. Gabriele Cerrone, has purchased 15,000 shares, increasing his total holding to 34.89% of the company's shares. The company is advancing its lead candidate, intranasal foralumab, a novel fully human anti-CD3 monoclonal antibody, currently in Phase 2a clinical trials for non-active secondary progressive …
ROMA Green Finance Limited has signed a non-binding letter of intent to invest US$15 million for a 5% equity stake in BlueFlare Group Holdings Inc., a developer of behind-the-meter power generation and distributed compute infrastructure focused on sub-10 MW data centers. This strategic investment is ROMA's first under its new AI/HPC infrastructure …
Aurora Mobile Limited has integrated Vidu Q3-Mix, a new video generation model developed by ShengShu Technology, into its Modellix unified AI media platform. The Vidu Q3-Mix enhances AI-driven video content creation with improved stability, camera control, and multi-character dialogue support, targeting sectors like advertising, e-commerce, AI dram…
Pharvaris reported compelling Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 clinical data showing oral deucrictibant's rapid, effective, and well-tolerated treatment of hereditary angioedema (HAE) attacks, both on-demand and as prophylaxis. Data demonstrate rapid symptom relief, high single-capsule efficacy rates, sustained attack prevention, and a favora…
Castellum, Inc., a cybersecurity and software services company focused on the federal government, announced that its joint venture, CTM JV, LLC, has secured a position on the U.S. Navy's Logistics IT Integration and Support Capability Modernization, Deployment, and Support Multiple Award Contract with a maximum total value of approximately $250 mil…
Genco Shipping & Trading Limited, a leading U.S.-based drybulk shipowner, strongly encourages shareholders to vote in favor of its incumbent board of directors and against handpicked nominees from Diana Shipping Inc. ahead of the company's June 18, 2026 annual meeting. Supported by top proxy advisory firms ISS, Glass Lewis, and Egan-Jones, the comp…
Parsons Corporation has secured a $184 million indefinite-delivery/indefinite-quantity contract from the U.S. Department of the Navy to support the Intelligence Carry-On Program. This program delivers ruggedized, portable workstations aimed at improving battlespace awareness and readiness for military operators in challenging environments, reinforc…
Context Therapeutics Inc. announced positive interim results from its ongoing Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody for solid tumors, in patients with heavily pretreated platinum-resistant ovarian cancer (PROC). The trial showed a 29% confirmed overall response rate and a favorable safety profile with …
